<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118222</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU4303</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-4303</secondary_id>
    <secondary_id>CWRU-00003937</secondary_id>
    <secondary_id>CWRU-4303</secondary_id>
    <nct_id>NCT00118222</nct_id>
  </id_info>
  <brief_title>High Light and Low Light Dose PDT in Glioma</brief_title>
  <official_title>A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active&#xD;
      when it is exposed to a certain kind of light. When the drug is active, tumor cells are&#xD;
      killed. Giving photodynamic therapy after surgery may kill any remaining tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying two different light doses of photodynamic&#xD;
      therapy using porfimer sodium to compare how well they work in treating patients who are&#xD;
      undergoing surgery for recurrent malignant astrocytoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare survival of patients undergoing surgical resection for recurrent high-grade&#xD;
           malignant supratentorial astrocytoma treated with intraoperative high vs low light dose&#xD;
           photodynamic therapy using porfimer sodium.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      participating center. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor&#xD;
      resection.&#xD;
&#xD;
        -  Arm I: During surgery, patients receive low light dose photodynamic therapy.&#xD;
&#xD;
        -  Arm II: During surgery, patients receive high light dose photodynamic therapy. After&#xD;
           completion of study treatment, patients are followed at 1 day, 6 weeks, and 3 months and&#xD;
           then every 3 months for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 120 patients will be accrued for this study within 4-5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression and survival measured</measure>
    <time_frame>at 4-6 weeks post-operatively and then every 3-4 months thereafter</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Low light dose during surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm I: During surgery, patients receive low light dose photodynamic therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High light dose during surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm II: During surgery, patients receive high light dose photodynamic therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>porfimer sodium</intervention_name>
    <description>All patients receive porfimer sodium IV.</description>
    <arm_group_label>High light dose during surgery</arm_group_label>
    <arm_group_label>Low light dose during surgery</arm_group_label>
    <other_name>dihematoporphyrin ether</other_name>
    <other_name>Photofrin II</other_name>
    <other_name>Porfimer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <description>All patients receive porfimer sodium IV.</description>
    <arm_group_label>High light dose during surgery</arm_group_label>
    <arm_group_label>Low light dose during surgery</arm_group_label>
    <other_name>dihematoporphyrin ether</other_name>
    <other_name>Photofrin II</other_name>
    <other_name>Porfimer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.</description>
    <arm_group_label>High light dose during surgery</arm_group_label>
    <arm_group_label>Low light dose during surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant supratentorial astrocytoma, glioblastoma, or mixed&#xD;
             oligo-astrocytoma&#xD;
&#xD;
               -  Grade 3 or 4 tumor, defined as presence of â‰¥ 2 of the following features:&#xD;
&#xD;
                    -  Nuclear atypia&#xD;
&#xD;
                    -  Mitosis&#xD;
&#xD;
                    -  Endothelial proliferation&#xD;
&#xD;
                    -  Necrosis&#xD;
&#xD;
          -  Recurrent disease&#xD;
&#xD;
               -  Failed prior surgery and radiotherapy&#xD;
&#xD;
          -  Tumor suitable for radical resection by imaging studies&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Willing to avoid direct sun-light exposure for 6 weeks after photodynamic therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J. Maciunas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2005</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert Maciunas, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihematoporphyrin Ether</mesh_term>
    <mesh_term>Hematoporphyrin Derivative</mesh_term>
    <mesh_term>Ether</mesh_term>
    <mesh_term>Trioxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

